Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aristolochia longa is a perennial plant species in the Aristolochiaceae family, commonly known as long aristolochia or Berrostom. It is native to North Africa and parts of the Mediterranean. The rhizomes (roots) are most often used in traditional medicine, particularly in Algeria and Morocco, where they are applied for ailments such as cancer, skin infections, diabetes, arthritis, and more[5][6]. Extracts from A. longa have demonstrated various biological activities in vitro including anticancer (cytotoxic), antibacterial, antifungal, antiparasitic, antiviral, anti-inflammatory, antioxidant effects[2][5][6]. The mechanisms underlying these effects are attributed to its rich content of bioactive compounds such as polyphenols (notably flavonoids), alkaloids, glycosides, tannins, terpenoids and saponins[6]. However—like all Aristolochia species—A. longa contains aristolochic acid which is both nephrotoxic (damages kidneys) and carcinogenic; use can result in kidney failure or urinary tract cancers[3][4]. Due to these severe toxicities it has been banned or restricted by health authorities worldwide.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aristolochia longa.